Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 6—June 2010


Invasive Aspergillosis after Pandemic (H1N1) 2009

Asma Lat, Nahid Bhadelia, Benjamin Miko, E. Yoko Furuya, and George R. ThompsonComments to Author 
Author affiliations: New York–Presbyterian Hospital, New York, New York, USA (A. Lat, N. Bhadelia, B. Miko, E. Yoko Furuya); University of California, Davis, Sacramento, California, USA (G.R. Thompson III)

Cite This Article


Highlight and copy the desired format.

EID Lat A, Bhadelia N, Miko B, Furuya EY, Thompson GR. Invasive Aspergillosis after Pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16(6):971-973.
AMA Lat A, Bhadelia N, Miko B, et al. Invasive Aspergillosis after Pandemic (H1N1) 2009. Emerging Infectious Diseases. 2010;16(6):971-973. doi:10.3201/eid1606.100165.
APA Lat, A., Bhadelia, N., Miko, B., Furuya, E. Y., & Thompson, G. R. (2010). Invasive Aspergillosis after Pandemic (H1N1) 2009. Emerging Infectious Diseases, 16(6), 971-973.


We report 2 patients with invasive aspergillosis after infection with pandemic (H1N1) 2009. Influenza viruses are known to cause immunologic defects and impair ciliary clearance. These defects, combined with high-dose corticosteroids prescribed during influenza-associated adult respiratory distress syndrome, may be novel risk factors predisposing otherwise immunocompetent patients to invasive aspergillosis.

Invasive aspergillosis has emerged as a major cause of life-threatening infections in immunocompromised patients. Patients with prolonged neutropenia, inherited immunodeficiency, or those receiving immunosuppressive agents are at risk for infection (1). Recent evidence has identified other populations at risk for invasive aspergillosis, including those with chronic obstructive pulmonary disease (COPD) and nontransplant patients in intensive care units (ICUs) (2,3). We recently treated 2 immunocompetent patients who had invasive aspergillosis after infection with pandemic (H1N1) 2009 and are aware of similar cases at other centers (4).

Influenza strains have been reported to cause cell-mediated defects, disruption of normal ciliary clearance (5), and leukopenia (6). These abnormalities and use of high-dose corticosteroids during treatment for influenza-associated acute respiratory distress syndrome (ARDS) may form a unique group of risk factors for invasive aspergillosis.

The Patients

Patient 1 was a 28-year-old man (college student) with no unusual medical history (body mass index 18 kg/m2) who was hospitalized after having shortness of breath for 1–1.5 weeks. Upon admission, he required intubation for respiratory failure. A chest radiograph showed multilobar pneumonia. His condition was complicated by pneumothoraces and bronchopleural fistula formation secondary to barotrauma during mechanical ventilation. A nasopharyngeal influenza swab specimen obtained at admission was positive for influenza A by PCR and was confirmed as pandemic (H1N1) 2009 by the New York State Health Department. Results of bronchoscopic evaluation for copathogens were negative. The patient was not treated with antivirus medication during his hospitalization because the diagnosis was made outside the optimal treatment time frame.

He received high-dose methylprednisolone (1 mg/kg/day) for ARDS for 28 days and later underwent bronchoscopy because of poor clinical improvement. Necrosis of the airway wall and cartilage, with extensive hyphae, was found and tissue cultures showed Aspergillus fumigatus. Intravenous voriconazole was initiated (6 mg/kg every 12 h [2 doses], then 4 mg/kg every 12 h for 24 days), but his clinical condition deteriorated; micafungin (100 mg/d) was added and continued for 14 days until he was transferred to another hospital on day 52.

On admission, tests showed lymphopenia (700 cells/mm3) and renal and respiratory failure. A. fumigatus was isolated from sputum, bronchoscopy, and pleural fluid cultures. A computed tomographic scan of the chest showed multifocal pneumonia. He was initially treated with amphotericin B lipid complex, cefepime, metronidazole, tobramycin, and vancomycin. The patient became hemodynamically unstable and required multiple vasopressors. On day 70, he had cardiopulmonary arrest and died. An autopsy was not performed.

Patient 2 was a 51-year-old man (office worker) with no unusual medical history (body mass index 24.5 kg/m2) who was hospitalized for fatigue and fever (<104°F). A chest radiograph showed bilateral infiltrates. Laboratory tests showed a leukocyte count of 1,500 cells/mm3 and a thrombocyte count of 65,000 cells/mm3. A bone marrow biopsy specimen was negative for malignancy. A computed tomographic scan of the chest showed diffuse alveolar consolidation. Broad-spectrum antimicrobial drugs (vancomycin, aztreonam, azithromycin, and fluconazole) were given but the patient’s respiratory status rapidly deteriorated and he was intubated on hospital day 2. Bronchoscopy showed alveolar hemorrhage, and he underwent video-assisted thoracoscopy and right lung wedge resection.

Virus cultures were positive for influenza A and verified as pandemic (H1N1) 2009 by the New York State Health Department. Antiviral treatment was not started because the diagnosis was made >48 hours after the onset of symptoms. A lung biopsy specimen showed widespread alveolar hemorrhage without fungal elements. Development of ARDS prompted administration of methylprednisolone (1 mg/kg/day for 3 days); his fever was quickly reduced. Once the methylprednisolone dose was tapered, fever recurred. Bronchoscopy on day 12 showed spontaneous bleeding from the right middle lobe and multiple blood clots. Pathologic examination identified fungal hyphae and A. fumigatus grew in culture. Treatment with intravenous voriconazole (6 mg/kg every 12 h [2 doses], followed by 4 mg/kg every 12 h) was initiated and continued for 3 days until he was transferred to another hospital on day 16.

At the new hospital, broad-spectrum antimicrobial therapy (linezolid, cefepime, tobramycin, oseltamivir, and voriconazole) was initiated. The patient showed decompensation over the next 72 h; his family withdrew care on day 21, and the patient died later that day. An autopsy showed severe pulmonary congestion, hemorrhage, and acute necrotizing bronchopneumonia. Several fungal abscesses consistent with Aspergillus spp. were identified in the lung, thyroid gland, and liver.


The number of patients at risk for invasive aspergillosis continues to increase. Recently, patients with COPD who are receiving long-term corticosteroids and immunocompetent ICU patients have been identified as nontraditional hosts at risk for invasive aspergillosis. Mortality rates in these groups are high, ≈95% in COPD patients (2) and 80% in ICU patients (3). However, infection with influenza and other respiratory viruses may pose a similar risk for invasive aspergillosis. Despite these high mortality rates, this association remains largely unnoticed (710). Thus, Aspergillus spp. observed in bronchoscopically obtained cultures from ICU patients diagnosed with pandemic (H1N1) 2009 may be overlooked as a contaminant despite their potential to cause invasive disease.

Infection with influenza virus is known to cause cell-mediated defects, disruption of normal ciliary clearance after infection (5), and leukopenia (6). These symptoms may predispose patients for invasive fungal disease. Additionally, ARDS (11) and immunodysregulation (12) may develop in patients with pandemic (H1N1) 2009. Severe structural lung disease apparent in this syndrome may also impair ciliary clearance, further predisposing these patients to invasive infections. Data suggest a potential benefit of corticosteroids in treating ARDS patients (13). Although potentially life-saving, high-dose corticosteroids, combined with structural and immunologic abnormalities observed in patients with pandemic (H1N1) 2009, may predispose patients to invasive aspergillosis. Development of this disease after influenza may be a rare complication, but infection with pandemic (H1N1) 2009 is widespread, thus placing many patients at risk for invasive aspergillosis.

Previous studies of influenza-associated aspergillosis have reported mortality rates of 100% (710). However, most of these reports predate routine use of noninvasive markers of invasive appergillosis or availability of voriconazole. Previous reports were published before the availability of oseltamivir, and specific antivirus therapy has been shown to decrease the incidence of influenza-associated complications (14,15). Early treatment with oseltamivir may have prevented complications seen in our patients.

Although intubated ICU patients commonly undergo bronchosopy, lack of a positive culture or direct smear result does not rule out a diagnosis of invasive aspergillosis (3). Moreover, although radiographic imaging may suggest aspergillosis, invasive diagnostic tests may be impractical when patients are hemodynamically unstable or have severe hypotoxicity, thrombocytopenia, or advanced coagulation deficits (1). Before serum testing for galactomannan, these patients would have satisfied criteria only for possible invasive aspergillosis and appropriate treatment could have been withheld. However, assays for detection of serum galactomannan or 1–3-β-D glucan and compatible imaging studies can aid in the diagnosis of probable invasive aspergillosis and thus the initiation of appropriate antifungal therapy. With increased awareness of invasive aspergillosis in nontraditional hosts, high mortality rates in patients with this disease can be avoided.

In conclusion, we report 2 patients with invasive aspergillosis after infection with pandemic (H1N1) 2009. Development of ARDS, structural lung disease, high doses of corticosteroids, and T-cell defects during infection with influenza viruses may be responsible for an emerging group of patients at high risk for invasive aspergillosis. Early diagnostic and treatment strategies should be used for these patients, and multicenter studies are needed to better define incidence and outcomes.

Dr Lat is a clinical manager of infectious diseases in the Department of Pharmacy at New York–Presbyterian Hospital, Columbia University Medical Center. Her research interests are antifungal therapy and fungal diagnostics.


  1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:32760. DOIPubMed
  2. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30:782800. DOIPubMed
  3. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:6215. DOIPubMed
  4. Chen TK, Babbitt CJ, Maggi C, Abbosaida A, Randhawa I, Walsh TJ. Pulmonary aspergillosis following H1N1 influenza A infection in pediatric patients. In: Programs and Abstracts of the 20th Annual Focus on Fungal Infections. New Orleans, LA: 2010 Mar 3–5. Alpharetta (GA): Imedex, LLC. Poster P-0026.
  5. Lewis DE, Gilbert BE, Knight V. Influenza virus infection induces functional alterations in peripheral blood lymphocytes. J Immunol. 1986;137:377781.PubMed
  6. Sedger LM, Hou S, Osvath SR, Glaccum MB, Peschon JJ, van Rooijen N, Bone marrow B cell apoptosis during in vivo influenza virus infection requires TNF-alpha and lymphotoxin-alpha. J Immunol. 2002;169:6193201.PubMed
  7. Lewis M, Kallenbach J, Ruff P, Zaltzman M, Abramowitz J, Zwi S. Invasive pulmonary aspergillosis complicating influenza A pneumonia in a previously healthy patient. Chest. 1985;87:6913. DOIPubMed
  8. Fischer JJ, Walker DH. Invasive pulmonary aspergillosis associated with influenza. JAMA. 1979;241:14934. DOIPubMed
  9. Clancy CJ, Nguyen MH. Acute community-acquired pneumonia due to Aspergillus in presumably immunocompetent hosts: clues for recognition of a rare but fatal disease. Chest. 1998;114:62934. DOIPubMed
  10. Boots RJ, Paterson DL, Allworth AM, Faoagali JL. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax. 1999;54:10479. DOIPubMed
  11. Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators, Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N, et al. Extracorporealv membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA. 2009;302:188895. DOIPubMed
  12. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50:8509. DOIPubMed
  13. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354:167184. DOIPubMed
  14. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302:1896902. DOIPubMed
  15. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother. 2010;65(Suppl 2):ii1124. DOIPubMed
Cite This Article

DOI: 10.3201/eid1606.100165

Table of Contents – Volume 16, Number 6—June 2010

Article Navigation


Please use the form below to submit correspondence to the authors or contact them at the following address:

George R. Thompson III, Department of Internal Medicine, Division of Infectious Diseases, University of California, Davis, 4150 V St, Ste 3400, Sacramento, CA 95817, USA

character(s) remaining.

Comment submitted successfully, thank you for your feedback.